Novigenix is a Lausanne, Switzerland–based biotech that develops and commercializes immuno‑transcriptomic precision oncology solutions. Its Liquid Immuno‑Transcriptomic (LITOseek) platform derives cancer‑specific immuno‑transcriptomic profiles from blood and combines them with multimodal clinical data. The company has validated its approach in colorectal cancer (CRC) screening and provides molecular insights and predictive algorithms for patient stratification and monitoring of immunotherapies. Novigenix is led by CEO Dr. Brian Hashemi. It raised $20M in a Series B and intends to use the proceeds to fast‑track clinical validation of a second‑generation NGS‑based liquid biopsy CRC screening assay and to develop new immunotherapy patient stratification assays. The platform focuses on predicting response to therapy at baseline and on treatment monitoring following therapy.

Total raised

$20M

Funding rounds

1

Latest round

Series B

Latest activity

Dec 2022